NIOX Group Plc

DB:82C Stock Report

Market Cap: €311.7m

NIOX Group Valuation

Is 82C undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 82C when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 82C (€0.73) is trading below our estimate of fair value (€1.22)

Significantly Below Fair Value: 82C is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 82C?

Key metric: As 82C is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 82C. This is calculated by dividing 82C's market cap by their current earnings.
What is 82C's PE Ratio?
PE Ratio23.7x
EarningsUK£11.00m
Market CapUK£260.28m

Price to Earnings Ratio vs Peers

How does 82C's PE Ratio compare to its peers?

The above table shows the PE ratio for 82C vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average22.5x
SBS Stratec
35x25.4%€350.7m
EUZ Eckert & Ziegler
21.1x4.5%€795.9m
PUS PULSION Medical Systems
26.7xn/a€134.4m
DRW3 Drägerwerk KGaA
7.2x2.0%€792.7m
82C NIOX Group
23.7x17.1%€260.3m

Price-To-Earnings vs Peers: 82C is expensive based on its Price-To-Earnings Ratio (23.7x) compared to the peer average (22.5x).

Price to Earnings Ratio vs Industry

How does 82C's PE Ratio compare vs other companies in the European Medical Equipment Industry?

3 CompaniesPrice / EarningsEstimated GrowthMarket Cap
82C 23.7xIndustry Avg. 28.9xNo. of Companies7PE01632486480+
3 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 82C is good value based on its Price-To-Earnings Ratio (23.7x) compared to the European Medical Equipment industry average (29.7x).

Price to Earnings Ratio vs Fair Ratio

What is 82C's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

82C PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio23.7x
Fair PE Ratio19.5x

Price-To-Earnings vs Fair Ratio: 82C is expensive based on its Price-To-Earnings Ratio (23.7x) compared to the estimated Fair Price-To-Earnings Ratio (19.5x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 82C forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€0.73
€0.98
+33.7%
10.1%€1.09€0.83n/a5
Nov ’25€0.72
€0.98
+35.6%
10.1%€1.09€0.83n/a5
Oct ’25€0.73
€0.97
+31.6%
9.2%€1.08€0.83n/a5
Sep ’25€0.76
€0.95
+26.0%
10.5%€1.07€0.79n/a5
Aug ’25€0.71
€0.95
+34.0%
10.5%€1.07€0.79n/a5
Jul ’25€0.78
€0.92
+17.9%
13.9%€1.06€0.74n/a4
Jun ’25€0.79
€0.92
+16.4%
13.9%€1.06€0.74n/a4
May ’25€0.80
€0.89
+11.8%
10.5%€1.02€0.74n/a5
Apr ’25€0.72
€0.89
+23.5%
10.5%€1.02€0.74n/a5
Mar ’25€0.70
€0.88
+25.4%
10.9%€1.01€0.72n/a5
Feb ’25€0.67
€0.88
+32.9%
10.9%€1.01€0.72n/a5
Jan ’25€0.70
€0.87
+24.2%
10.0%€1.00€0.71n/a6
Dec ’24€0.72
€0.87
+20.0%
10.0%€1.00€0.71n/a6
Nov ’24€0.71
€0.90
+26.6%
5.9%€1.00€0.84€0.725
Oct ’24€0.75
€0.91
+21.5%
6.5%€1.00€0.84€0.734
Sep ’24€0.76
€0.92
+21.0%
7.3%€1.02€0.83€0.764
Aug ’24€0.80
€0.86
+8.6%
4.1%€0.90€0.83€0.712
Jul ’24€0.63
€0.79
+25.3%
11.0%€0.91€0.70€0.783
Jun ’24€0.68
€0.79
+16.1%
11.0%€0.91€0.70€0.793
May ’24€0.51
€0.64
+25.8%
1.5%€0.65€0.62€0.803
Apr ’24€0.49
€0.64
+29.1%
1.5%€0.65€0.62€0.723
Mar ’24€0.51
€0.56
+11.5%
12.2%€0.63€0.47€0.703
Feb ’24€0.40
€0.56
+40.8%
12.2%€0.63€0.47€0.673
Jan ’24€0.38
€0.55
+46.7%
12.0%€0.64€0.47€0.703
Dec ’23€0.38
€0.55
+45.9%
12.0%€0.64€0.47€0.723
Nov ’23€0.40
€0.55
+37.2%
12.0%€0.64€0.47€0.713

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

Sensus Healthcare

US$125.2m

A medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide.

5TX

US$7.25

7D

16.0%

1Y

272.6%

Ship Healthcare Holdings

JP¥196.5b

Engages in the medical, healthcare, welfare, and nursing care businesses worldwide.

5EZ

JP¥12.40

7D

-3.1%

1Y

-4.6%

CVS Health

US$66.9b

Provides health solutions in the United States.

CVS

US$53.25

7D

2.4%

1Y

-14.7%